Patents by Inventor Jim Palmer

Jim Palmer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF MENIN-MLL INTERACTION
    Publication number: 20240140953
    Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
    Type: Application
    Filed: November 6, 2023
    Publication date: May 2, 2024
    Inventors: Thomas BUTLER, Jim PALMER, Ravi UPASANI, Matthew WELSCH, Sridhar VEMPATI, Brendan KELLY, Edward PAINTER
  • FLUORESCENT DYES
    Publication number: 20240093034
    Abstract: The present invention relates to fluorescent dyes of formula (I), including salts thereof, and extracellular vesicles and cells labelled with the fluorescent dyes. The present invention also relates to methods, uses and kits thereof.
    Type: Application
    Filed: December 24, 2021
    Publication date: March 21, 2024
    Applicant: EXOPHARM LIMITED
    Inventors: Jim PALMER, Ian DIXON, Patrick JAMES, Melanie SCHOPPET, Karmen KONG, Sebastian M. MARCUCCIO, Jonathan M. FABER, Kieran P. STOCKTON, Melissa WERRETT, Rohan JOYCE
  • Inhibitors of menin-mll interaction
    Patent number: 11845753
    Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: December 19, 2023
    Assignee: Biomea Fusion, Inc.
    Inventors: Thomas Butler, Jim Palmer, Ravi Upasani, Matthew Welsch, Sridhar Vempati, Brendan Kelly, Edward Painter
  • IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION
    Publication number: 20230391784
    Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
    Type: Application
    Filed: July 31, 2023
    Publication date: December 7, 2023
    Inventors: Thomas BUTLER, Jim PALMER, Ravi UPASANI, Matthew WELSCH, Sridhar VEMPATI, Brendan KELLY, Edward PAINTER
  • IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION
    Publication number: 20230227458
    Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
    Type: Application
    Filed: January 9, 2023
    Publication date: July 20, 2023
    Inventors: Thomas BUTLER, Jim PALMER, Ravi UPASANI, Matthew WELSCH, Sridhar VEMPATI, Brendan KELLY, Edward PAINTER
  • Substituted pyridines as irreversible inhibitors of menin-MLL interaction
    Patent number: 11702421
    Abstract: Disclosed herein are heterocyclic compounds according to formula (I) having the structure that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-HLL interaction. Also disclosed are pharmaceutical compositions that include compounds according to formula (I). Methods of using the menin-HLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
    Type: Grant
    Filed: June 18, 2021
    Date of Patent: July 18, 2023
    Assignee: BIOMEA FUSION, LLC
    Inventors: Thomas Butler, Jim Palmer, Ravi Upasani, Matthew Welsch, Sridhar Vempati, Brendan Kelly, Edward Painter
  • Methods and compositions for purification or isolation of microvesicles and exosomes
    Patent number: 11666603
    Abstract: The invention relates to the isolation or extraction of exosomes.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: June 6, 2023
    Assignee: EXOPHARM LIMITED
    Inventors: Chacko Joseph, Jim Palmer, Ian Dixon, Gregor Lichtfuss
  • Methods and compositions for purification or isolation of microvesicles and exosomes
    Patent number: 11559552
    Abstract: The invention relates to the isolation or extraction of exosomes.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: January 24, 2023
    Assignee: Exopharm Limited
    Inventors: Chacko Joseph, Jim Palmer, Ian Dixon, Gregor Lichtfuss
  • METHODS AND COMPOSITIONS FOR PURIFICATION OR ISOLATION OF MICROVESICLES AND EXOSOMES
    Publication number: 20220296646
    Abstract: The invention relates to the isolation or extraction of exosomes.
    Type: Application
    Filed: June 3, 2022
    Publication date: September 22, 2022
    Applicant: EXOPHARM LIMITED
    Inventors: Chacko JOSEPH, JIM PALMER, IAN DIXON, Gregor LICHTFUSS
  • IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION
    Publication number: 20220169627
    Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
    Type: Application
    Filed: June 18, 2021
    Publication date: June 2, 2022
    Inventors: Thomas Butler, Jim Palmer, Ravi Upasani, Matthew Welsch, Sridhar Vempati, Brendan Kelly, Edward Painter
  • INHIBITORS OF MENIN-MLL INTERACTION
    Publication number: 20220024936
    Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
    Type: Application
    Filed: September 10, 2021
    Publication date: January 27, 2022
    Inventors: Thomas BUTLER, Jim Palmer, Ravi Upasani, Matthew Welsch, Sridhar Vempati, Brendan Kelly, Edward Painter
  • Methods and compositions for purification or isolation of microvesicles and exosomes
    Patent number: 11202805
    Abstract: The invention relates to the isolation or extraction of exosomes.
    Type: Grant
    Filed: January 12, 2021
    Date of Patent: December 21, 2021
    Assignee: Exopharm Limited
    Inventors: Chacko Joseph, Jim Palmer, Ian Dixon, Gregor Lichtfuss
  • Inhibitors of menin-MLL interaction
    Patent number: 11174263
    Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 31, 2019
    Date of Patent: November 16, 2021
    Assignee: BIOMEA FUSION, INC.
    Inventors: Thomas Butler, Jim Palmer, Ravi Upasani, Matthew Welsch, Sridhar Vempati, Brendan Kelly, Edward Painter
  • Methods And Compositions For Purification Or Isolation Of Microvesicles And Exosomes
    Publication number: 20210245074
    Abstract: The invention provides methods and compositions for the isolation or extraction of exosomes or microvesicles. The methods and compositions may involve providing a device including exosome-binding ligands in the form of anionic or electron-rich groups arranged on a substrate surface. The methods and compositions may involve providing a device including a substrate having a surface, with a plurality of polymers attached to the substrate and exosome-binding ligands in the form of anionic or electron-rich groups arranged on the plurality of polymers.
    Type: Application
    Filed: June 18, 2019
    Publication date: August 12, 2021
    Applicant: Exopharm Limited
    Inventors: Gregor Lichtfuss, Jim Palmer, Ian Dixon
  • Substituted pyridines as irreversible inhibitors of menin-MLL interaction
    Patent number: 11084825
    Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL inter-action; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 31, 2019
    Date of Patent: August 10, 2021
    Assignee: BIOMEA FUSION, LLC
    Inventors: Thomas Butler, Jim Palmer, Ravi Upasani, Matthew Welsch, Sridhar Vempati, Brendan Kelly, Edward Painter
  • Methods And Compositions For Purification Or Isolation Of Microvesicles And Exosomes
    Publication number: 20210128632
    Abstract: The invention relates to the isolation or extraction of exosomes.
    Type: Application
    Filed: January 12, 2021
    Publication date: May 6, 2021
    Applicant: Exopharm Limited
    Inventors: Chacko Joseph, Jim Palmer, Ian Dixon, Gregor Lichtfuss
  • INHIBITORS OF MENIN-MLL INTERACTION
    Publication number: 20200255434
    Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
    Type: Application
    Filed: December 31, 2019
    Publication date: August 13, 2020
    Inventors: Thomas Butler, Jim Palmer, Ravi Upasani, Matthew Welsch, Sridhar Vempati, Brendan Kelly, Edward Painter
  • IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION
    Publication number: 20200223853
    Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
    Type: Application
    Filed: December 31, 2019
    Publication date: July 16, 2020
    Inventors: Thomas Butler, Jim Palmer, Ravi Upasani, Matthew Welsch, Sridhar Vempati, Brendan Kelly, Edward Painter
  • Methods And Compositions For Purification Or Isolation Of Microvesicles And Exosomes
    Publication number: 20200023012
    Abstract: The invention relates to the isolation or extraction of exosomes.
    Type: Application
    Filed: December 22, 2017
    Publication date: January 23, 2020
    Inventors: Chacko Joseph, Jim Palmer, Ian Dixon, Gregor Lichtfuss
  • Foundation system for electrical utility structures
    Patent number: 8677700
    Abstract: A foundation system for electrical utility structures is provided that minimizes impact on the chosen construction site, minimizes labor and minimizes associated installation costs. The foundation system comprises a structure to be supported at its base which has a plurality of arm members secured to the base and a plurality of helical piers or micropiles which are inserted into the ground and distally attached to the base of the structure by attaching to the arm members.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: March 25, 2014
    Assignee: Thomas & Betts International, Inc.
    Inventors: Mark Fairbairn, Aubrey Jackson, Ed Jacobs, Steve Moline, Thad Mumm, Jim Palmer